Aim: Diabetes has rapidly become an epidemic all over the world. In 2013, the prevalence of type 2 diabetes (T2D) in China was reported to be 10.4%. The Qinghai-Tibet Plateau is the world’s highest plateau, people lived in there usually have a high-calorie diet and low fruit and vegetable intake. The aim of this study was to describe the current control of HbA1c (A), blood pressure (B) and LDL-c (C) in patients with T2D from Tibet based on electronic medical records.
Methods: Patients aged 18-79 years with T2D documented from 2014 to 2018 were enrolled in this study. Clinical and biochemical characteristics were collected from EMRs. Control criteria were defined base on the 2017 Chinese Guidelines for the Prevention and Treatment of type 2 diabetes.
Results: A total of 1999 patients with type 2 diabetes were included in the study. The mean (SD) age of the subjects was 55.2 (10.5) years. The median diabetic duration was 7.0 (range: 0.1-32) years and 879 (43.9%) patients were female. Among patients, 653 (32.7%) patients had a normal weight (BMI < 24 Kg/m2), 874 (43.7%) patients were overweight (24 ≤ BMI < 28Kg/m2) and 472 patients were obesity (BMI ≥ 28 Kg/m2). Only 321 (16.1%) patients had controlled HbA1c concentration below 7.0%, 965 (48.3%) had poor controlled HbA1c (HbA1c < 9%). The prevalence of hypertension was 46.8% and 742 (37.1%) patients had controlled blood pressure (systolic blood pressure <130 mmHg and diastolic blood pressure < 80 mmHg). Controlled LDL-c concentration (<1.8 mmol/L with coronary heart disease and 2.6 mmol/L without the disease) was found in 1046 (52.3%) patients. In all patients, 848 (42.4%) patients achieved at least one target, 526 (26.3%) patients achieved at least two targets and only 70 (3.5%) patients achieved all three targets.
Conclusions: Despite the potential selection bias, the glycemic controls is quite low in the present study, even few patients achieved all ABC targets. More intensive T2DM management with complementary efforts is warranted in this population.
Z. Chenghui: None. L. Mingxia: None. W. Suyuan: None. W. Yunhong: None.